Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis
Year: 2026
Type: article
Study design: Observational Study
Source: American Journal of Hematology
DOI: 10.1002/ajh.70327
Authors: Elias Jabbour, Hannah Goulart, Koji Sasaki, Caitlin R. Rausch, Nitin Jain, Tapan M. Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban‐Bravo, Guillermo Garcia‐Manero, Danielle Hammond, Mahesh Swaminathan, Maria Hachem, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas J. Short, Hagop M. Kantarjian
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
Award: Cancer Center Support Grant
OpenAlex ID: W7155721790